Journal article

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

Simon Z He, Samantha Busfield, David S Ritchie, Mark S Hertzberg, Simon Durrant, Ian D Lewis, Paula Marlton, Andrew J McLachlan, Ian Kerridge, Kenneth F Bradstock, Glen Kennedy, Andrew W Boyd, Trina M Yeadon, Angel F Lopez, Hayley S Ramshaw, Harry Iland, Simone Bamford, Megan Barnden, Mark DeWitte, Russell Basser Show all

Leukemia & Lymphoma | INFORMA HEALTHCARE | Published : 2015

Grants

Awarded by National Health and Medical Research Council (NHMRC) of Australia


Funding Acknowledgements

This trial was funded by CSL Ltd.We thank all patients participating in the study, and the research nurses who worked with us during its conduct. We also thank Dr. David Gearing for his role in the preclinical development of CSL360, and for helpful discussions. We would like to thank Mark Biondo, Sarah Hosback and Rosyln Davis from CSL Ltd. for developing, validating and performing the pharmacodynamics and PK and immunogenicity assays. S.Z.H. was supported by a Webster scholarship (Melbourne Health) and Max Whiteside Clinical Fellowship (Leukaemia Foundation of Australia); A.W.R.'s work was supported by a fellowship from the Victorian Cancer Agency and grants (461219, 637309, 1016647) from the National Health and Medical Research Council (NHMRC) of Australia; A.F.L.'s work was supported by grants from the NHMRC and from Cancer Australia; H.S.R.'s work was supported by the Peter Nelson Leukaemia Research Fund.